New drug versus standard treatment for newly diagnosed AL amyloidosis
Part of Hormones & metabolism clinical trials.
This trial tests a new drug called NXC-201 against a standard combination treatment (daratumumab with cyclophosphamide, bortezomib, and dexamethasone) for people with newly diagnosed AL amyloidosis. The goal is to see if the new drug works better at targeting the abnormal proteins that cause organ damage.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been newly diagnosed with AL amyloidosis and have not yet had any treatment for it.
- You have at least one organ affected by AL amyloidosis, such as your heart, kidneys, or liver.
- You are generally able to care for yourself (ECOG performance status 0-2).
- You do not have a diagnosis of multiple myeloma (a related blood cancer).
- You are not in the most advanced stage of heart involvement (Stage 3b).
- You have not had another cancer in the past 3 years, and no stroke or seizure in the past 6 months.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests the drug daratumumab in people newly diagnosed with light chain amyloidosis that affects the heart, kidney, or liver. The goal is to see if daratumumab can help control the disease. Eligibility depends on your disease stage and overall health.
This trial tests a new drug (SCTC21C) combined with three standard chemotherapy medicines for people who have just been diagnosed with AL amyloidosis. The goal is to see if adding the new drug helps reduce the abnormal protein deposits better than the standard treatment alone.
This study tests a new medicine called etentamig against a standard combination therapy (Dara-CyBorD) for people with AL amyloidosis, a condition where abnormal proteins build up in organs. The goal is to see which treatment better controls the disease and has fewer side effects.
This trial tests a new drug (a bispecific antibody) for people newly diagnosed with AL amyloidosis, a condition where abnormal proteins build up and damage organs. The drug aims to target and clear these abnormal cells to help reduce organ damage.
This trial tests a new drug combination for people with a specific type of AL amyloidosis (light chain amyloidosis) that has a genetic marker called t(11;14). The treatment includes Sonrotoclax (a targeted therapy) plus steroids, and possibly another drug called daratumumab, to see if it can help control the disease.
This trial tests a new targeted medicine called elranatamab for people newly diagnosed with AL amyloidosis, a condition where abnormal proteins build up in organs. It aims to see if this treatment can help control the disease.
Hear when a new Light Chain (AL) Amyloidosis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.